1. Introduction {#sec0001}
===============

1.1. Post-stroke epilepsy {#sec0002}
-------------------------

Stroke is one of the most important causes of acquired epilepsy in the adult population ([@bib0001]). Management of post-stroke epilepsy is of great clinical significance as patients with seizures after stroke have higher mortality and disability than those without seizures ([@bib0002]). Furthermore, epilepsy impairs long-term functional outcomes in those who have suffered a stroke or transient ischaemic attack ([@bib0003]).

Several studies have investigated the development of seizures and epilepsy following stroke. The reported incidence varies significantly between studies; this likely reflects differences in definition, variable inclusion of patients with haemorrhagic stroke or subarachnoid haemorrhage, and significant clinical heterogeneity. Furthermore, most studies include both early and late seizures, with various definitions of early seizures ranging from seizures at the time of stroke onset to 2 weeks afterward. A cohort study of patients with ischemic stroke from our institution found an incidence of early onset seizures of 5% and late onset seizures of 10.1% over two years in 159 patients treated with IV rtPA, and 5.8% and 8% in 138 non rtPA treated patients ([@bib0004]). A systematic review and pooled analysis of 102,008 patients ([@bib0005]) showed an overall incidence of post-stroke seizures of 7%, with those with haemorrhagic stroke or cortical involvement at higher risk. There is evidence that stroke associated with venous sinus thrombosis also confers a higher risk of seizures ([@bib0006]).

1.2. Revised definition of post-stroke epilepsy {#sec0003}
-----------------------------------------------

According to the International League Against Epilepsy, acute symptomatic seizures are defined as those seizures occurring in close temporal association with a brain insult. This is reflected in the differentiation between "early" and "late" post-stroke seizures, with the latter defined as occurring more than 7 days after the stroke ([@bib0007]). While epilepsy has historically been defined as two or more unprovoked seizures, the revised ILAE definition of epilepsy from 2014 included individuals with one unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures, occurring over the next 10 years ([@bib0008]). Hence according to the new definition an individual experiencing one post-stroke seizure at least one month after stroke (or two seizures at least 7 days after stroke) can be diagnosed with epilepsy. This is consistent with previous observational studies that show most patients with one late post-stroke seizure will go on to develop recurrent seizures ([@bib0009]).

1.3. Risk factors for post-stroke epilepsy {#sec0004}
------------------------------------------

Galovic and colleagues recently proposed a multivariable prediction model for the development of late seizures after ischaemic stroke, drawing on five identified predictive factors of stroke severity, large artery atherosclerotic aetiology, early seizures, cortical involvement and middle cerebral artery territory involvement ([@bib0010]). Based on this algorithm, those at highest risk were determined to have a post-stroke epilepsy risk of 83% within five years.

Our research group has reported several risk factors for the development of post-ischaemic stroke seizures, including cortical involvement ([@bib0011]), a low Alberta Stroke Program Early CT Score (ASPECTS) score ([@bib0012]) and haemorrhagic transformation ([@bib0013]). We have also demonstrated that implementation of a code stroke system reduces the risk of post-stroke epilepsy ([@bib0014]).

1.4. Treatment and prevention of post-stroke epilepsy {#sec0005}
-----------------------------------------------------

While anti-epileptic drugs form the first line for management of post-stroke epilepsy the optimal timing and choice of drug have not been established. There have not been any randomised controlled trials comparing an anti-epileptic drug with placebo for the secondary prevention of post-stroke seizures (i.e. after the occurrence of one or more seizures). A recent Cochrane review commented on three randomised trials comparing different secondary prevention therapies ([@bib0015]), only one of which examined a cohort in which stroke was the only aetiology for the seizures ([@bib0016]). Across these studies lamotrigine was shown to be both efficacious and to have a superior tolerability profile to the other agents. Levetiracetam may also be a safe and effective option in elderly patients ([@bib0017]). Post-stroke seizures generally respond well to anti-epileptic drug treatment: Gilad and coworkers observed seizure freedom in 37/64 patients over a 12 month follow-up period ([@bib0016]).

Two studies have examined anti-epileptic drugs for the primary prevention of seizures after stroke (i.e. anti-epileptogenic therapy). [@bib0018]) studied whether the short-term (14 week) administration of levetiracetam would prevent the development of epilepsy after stroke. This study was prematurely terminated due to slow recruitment rates. A randomised controlled trial with a placebo group has examined the role of short-term antiepileptic therapy to prevent late seizures after haemorrhagic stroke ([@bib0019]); the authors found that treatment with sodium valproate for one month did not affect seizure risk. Our group has reported that patients developing haemorrhagic transformation after receiving reperfusion therapy for acute ischaemic stroke are at higher risk of epilepsy and may benefit from longer follow-up ([@bib0020]).

2. Glutamate {#sec0006}
============

For an effective anti-epileptogenic therapy to be developed, consideration needs to be given to the identification of biomarkers for patients at most risk of developing post-stroke seizures. While various studies have looked at the peri-stroke exposome and association with seizures, including relevant comorbidities, metabolic disturbance and concomitant pharmacotherapy, no other biomarkers have been identified ([@bib0021]).

Cerebral glutamate may be a biomarker of post-stroke seizures. Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system and plays a key role in normal brain function. Most brain glutamate is present intracellularly however as glutamate receptors are located on the cell surface its extracellular concentration determines the extent of stimulation ([@bib0022]). Glutamate-mediated excitotoxicity refers to the process by which excessive stimulation of glutamate receptors induces neuronal cell death, a process implicated in several neurological disorders including stroke, epilepsy, brain trauma and chronic neurodegenerative disorders ([@bib0023]). Overstimulation of glutamate receptors induces cell death by multiple effects including impairment of intracellular calcium homeostasis, activation of proteases and kinases, increased nitric oxide and expression of pro-death transcription factors ([@bib0023]).

Activation of glutamate receptors has been shown to contribute to ischaemic cell death in stroke by impairing ion homeostasis with a resultant increase in intracellular calcium concentration ([@bib0024]). Tissue oedema arises through influx of sodium and chloride ions and subsequently water, impairing perfusion of regions surrounding the ischaemic core.

It is well documented however that changes in the strength of excitatory synapses play an important role in synaptic plasticity ([@bib0025]) and it is postulated that glutamate receptor signalling may therefore play a different role in the recovery from stroke to during the phase of acute ischaemia ([@bib0026]). Among the evidence supportive of this theory is the observation that motor recovery is enhanced by increased α--amino-3-hydroxy-5-methyld-4-isoxazolepropionic acid (AMPA) receptor signalling ([@bib0027]). Chronic treatment with the N-methyl D-aspartate (NMDA) receptor antagonist memantine, however, improved recovery from stroke in an animal model ([@bib0028]).

2.1. Glutamate and stroke {#sec0007}
-------------------------

In animal models, acute elevation of glutamate levels have been observed after stroke ([@bib0029]) with the highest elevations seen in those with the largest infarctions. Other studies however have demonstrated a decrease in glutamate levels, postulated due to a combination of decreased glutamate synthesis and loss of brain glutamate via cerebrospinal fluid and the systemic circulation ([@bib0030]). In human studies, elevated intra-cerebral glutamate levels, as measured from cerebrospinal fluid, have been demonstrated in acute stroke ([@bib0031]) with glutamate levels in both CSF and plasma correlated with infarction lesion and severity of neurological deficit (see [Fig. 1](#fig0001){ref-type="fig"}). Glutamate elevation has also been implicated in the pathogenesis of haemorrhagic stroke, however this may involve a different mechanism through Src kinase activation and phosphorylation of glutamate receptors ([@bib0032]).Fig. 1The relationship between infarct volume and glutamate levels, from [@bib0031].Fig. 1

2.2. Glutamate and epilepsy {#sec0008}
---------------------------

The glutamate/GABA hypothesis of epilepsy is one of the extensively researched theories of epileptogenesis. Several aspects of the glutamate pathway have been studied, including neuro- and glio- transmission of glutamate, sensing transmitter molecules and the role of glutamate and GABA receptors ([@bib0033]).

Changes in glutamate levels in the human epileptic brain are well established. [@bib0034]) measured glutamate and GABA concentrations by microdialysis in six patients with temporal lobe epilepsy undergoing epilepsy surgery, identifying high levels of glutamate in the epileptogenic hippocampus both prior to and during seizures, therefore concluding that the rise in extracellular glutamate may precipitate seizures. Cavus et al. performed microdialysis studies on 79 patients at the Yale epilepsy surgery program ([@bib0035]). The authors demonstrated elevated glutamate levels in epileptogenic, non-localised and lesional cortical sites when compared to non-epileptogenic cortex. They also found elevated glutamate levels in epileptogenic compared with non-epileptogenic hippocampus. Our group have reported elevated glutamate levels in the tumours and surrounding peri‑tumoural cortex in resected tissue from patients with brain tumour-related epilepsy compared to those with histologically similar brain tumours without epilepsy ([@bib0036]; [@bib0037]).

There are other lines of evidence implicating glutamate in the pathogenesis of epilepsy and epileptogenesis. Changes in excitatory and inhibitory glutamate transporters, for example, have been observed in epileptogenic brain regions ([@bib0038]), and experimentally altering the function of glutamate receptor proteins can induce epilepsy syndromes ([@bib0039]).

2.3. Modulation of glutamate levels as a therapeutic target {#sec0009}
-----------------------------------------------------------

The experience with glutamate receptor antagonists in stroke has however been a disappointing one. For example, despite observed neuroprotective properties in animal studies, clinical trials of the NMDA receptor antagonist selfotel were stopped prematurely due to a trend toward increased mortality in the treatment group ([@bib0040]) with similar failures observed in the setting of traumatic brain injury ([@bib0041]). A trial of the AMPA receptor antagonist ZK200775 was also stopped due to transient neurological deterioration in the treatment group ([@bib0042]). While some have cited pharmacokinetic factors and poor trial design as possible explanations for the failure, it has also been postulated that synaptic activity mediated by NMDA receptors may promote survival of neurons in this setting ([@bib0043]).

Several studies have looked at the role of modulators of the glutamate pathway in both treating epilepsy and preventing epileptogenesis. A well-known example is the non-competitive, selective AMPA receptor antagonist perampanel, approved as adjunctive treatment for refractory focal and generalised seizures based on demonstrated efficacy in several multi-centre randomised trials of patients with uncontrolled focal and generalised seizures ([@bib0044]). While it is not known if perampanel has anti-epileptogenic properties in humans, in animal studies it has been shown to modulate the development of epilepsy induced by kindling techniques ([@bib0045]). It has also been shown to improve cognitive outcome after middle cerebral artery occlusion in rats although the association with development of seizures was not specifically studied ([@bib0046]).

Numerous other studies have demonstrated attenuation of epileptogenesis through modulation of both ionotropic and metabotropic glutamate receptors. Administration of pre-synaptic metabotropic glutamate agonists has been shown to block the development of epileptogenesis, correlated with a decrease in glutamate release from cortical synaptosomes ([@bib0047]) as has antagonism of excitatory metabotropic receptors prior to administration of pilocarpine ([@bib0048]). NMDA receptor antagonists have been shown to suppress the development of epilepsy from amygdala kindling ([@bib0049]) and antagonism of both NMDA and AMPA receptors concurrently has been shown to attenuate kindling while slowing the development of pathological changes ([@bib0050]).

Several studies have induced experimental stroke by means of prothrombosis or middle cerebral artery occlusion although the rate of development of seizures is variable and differs depending on the type of stroke induction ([@bib0021]). In one study, the administration of the pyrrolidone derivative nefiracetam reduced the frequency and duration of non-convulsive seizures when administered 15 min after middle cerebral artery occlusion ([@bib0051]) and also protected against neuronal cell death induced by glutamate in the in vitro setting. The non-competitive AMPA receptor antagonist EGIS-8332 demonstrated both anticonvulsant properties as well as neuroprotective effects against ischaemic injury induced by several mechanisms ([@bib0052]).

2.4. Modelling post-stroke epileptogenesis: the role of glutamate {#sec0010}
-----------------------------------------------------------------

Despite the evidence implicating glutamate in both stroke and epilepsy, there is little data examining the relationship between the rise in glutamate during acute stroke with the risk of developing subsequent seizures. [@bib0053]) demonstrated elevated plasma glutamate levels and decreased calcium levels in stroke patients with early seizures (within 72 h) compared with those without seizures although the effect on development of late seizures remains unclear.

In-vitro methods have also been employed. In one such study, injury was induced by exposure of cultured neurons to glutamate, a process analogous to glutamate-mediated cell death in stroke, with Spontaneous Recurrent Epileptiform Discharges (SREDs) observed in surviving neurons. The same authors have shown that glutamate injury-induced epileptogenesis is calcium-dependent and is blocked by administration of a noncompetitive NMDA receptor antagonist ([@bib0054]). Some authors have contended however that exposure to glutamate in vitro is not analogous to in-vivo ischaemic injury as the metabolic and biochemical responses are different ([@bib0055]).

2.5. The role of imaging {#sec0011}
------------------------

One of the inherent challenges in searching for biomarkers of post-stroke seizures is that quantification of intracerebral metabolites has relied on direct measurement from brain tissue or cerebrospinal fluid. The advent of 7T MRI technology represents an opportunity for imaging-based quantification of intracerebral metabolites in vivo. Magnetic Resonance Spectroscopy (MRS) studies of stroke at lower field strengths have demonstrated prolonged elevations in lactate and reduced N-acetylasparatate (NAA), thought to be a surrogate marker of cell survival or loss ([@bib0056]). While glutamate is difficult to separate from glutamine and GABA at 1.5 and 3T, [@bib0057]) observed increased glutamate as part of a metabolic signature including elevated lactate and NAA in hyper-perfused brain tissue after reperfusion therapy. Interestingly this pattern was associated with better clinical outcomes after reperfusion.

MRS has also been used extensively in the study of epilepsy. A systematic review of MRS studies in juvenile myoclonic epilepsy identified metabolic changes across a range of brain regions including the thalamus, frontal lobe insula and striatum ([@bib0058]). Regional increases in the glutamate-glutamine complex (Glx) may be the result of hyperexcitability ([@bib0059]).

Several studies of focal epilepsy have showed reduced NAA ipsilateral to seizure focus, ([@bib0060]; [@bib0061]; [@bib0062]) including in non-lesional cases ([@bib0063]) and the glutamine plus glutamate (Glx) to NAA and Choline ratios can correctly identify the epileptogenic zone in patients with temporal lobe epilepsy ([@bib0064]). In an MRS study of focal cortical dysplasia ([@bib0065]), patients had elevated levels of glutamine/glutamate and reduced levels of NAA compared with controls. Other studies have shown that higher concordance between MRS abnormalities and region of surgical resection is associated with better surgical outcomes ([@bib0066]).

For measurement of glutamate, PRESS and MEGA-PRESS techniques have shown excellent in vitro agreement between actual and measured glutamate concentrations, as well as good repeatability at 3T ([@bib0067]). Clinically, elevated glutamate concentrations have been associated with seizures in a population of glioma patients with epilepsy ([@bib0068]) and another study showed a correlation between glutamine/glutamate (Glx) levels on MRS and frequency and duration of seizures in neonatal hypoxic-ischaemic encephalopathy ([@bib0069]).

Glutamate is difficult to separate from glutamine at 1.5T; at higher field strengths, improved separation is possible although factors such as increased B0 and B1 inhomogeneities may pose technical challenges ([@bib0070]). Other challenges cited include the inadequacy of single voxel spectroscopy due to the potential dilution of small abnormalities by partial volume effects and the need to cover wide brain territories ([@bib0066]). Therefore, MRS is yet to have an established role in the routine management of what is such a heterogeneous group of disorders ([@bib0071]).

Glutamate can be measured non-invasively with an ultra-high field (7T) MRI technique called Glutamate Chemical Exchange Saturation Transfer (*GluCEST*)*,* developed at the University of Pennsylvania ([@bib0072]). CEST techniques exploit the ability to image metabolites based on their water protein exchange rates ([@bib0073]). The main advantage of GluCEST over MRS is its ability to provide increased spatial and temporal resolution ([@bib0072]). In vitro, the GluCEST effect is proportional to glutamate concentration at pH 7 and there is consistency between GluCEST contrast and both ^1^MRS glutamate signal and PET imaging of the distribution of glutamate receptors. This technique has been used to localise epileptic foci in non-lesional focal epilepsy ([@bib0074]) but has not been used to study a human stroke population. Neal et al. recently demonstrated that increased peritumoural GluCEST contrast is associated with both recent seizures and drug refractory epilepsy in patients with glioma ([Fig. 2](#fig0002){ref-type="fig"}) ([@bib0075]).Fig. 2Magnetic Resonance Spectrum at 7T (left). Axial GluCEST image (right) demonstrating increased GluCEST contrast in a glioma patient. From [@bib0075].Fig. 2

2.6. Potential problems with the glutamate hypothesis {#sec0012}
-----------------------------------------------------

Despite the strong evidence implicating glutamate-related excitotoxicity in the pathogenesis of stroke, experimental treatment with glutamate antagonists has proved ineffective to improve functional outcome, although the impact on development of seizures was not studied. There are several explanations put forward for this failure, discussed in depth by [@bib0055]). Several of these theories may be relevant to our understanding of post-stroke epileptogenesis.

One problem is the extent of release of glutamate in the ischaemic core compared with the ischaemic penumbra and its association with epileptogenesis: experimental data suggests it is the ischaemic penumbra rather than the core that is responsible for epileptogenesis ([@bib0054]), consistent with the hypothesis that dead neurons do not generate epileptiform discharges, although in animal models of ischaemia the extent of elevation of extracellular glutamate levels is significantly higher in the core ([@bib0076]). Furthermore the toxic effect of glutamate may be offset by the neuroprotective effect of extracellular acidity in the setting of acute stroke ([@bib0077]); it is possible though that tissue acidosis may protect against infarct growth but not against the cellular excitability and altered calcium homeostasis observed in the structurally intact penumbra. It is also unclear if the deleterious effects of glutamate toxicity are in any way offset by the concurrent rise in extracellular levels of the inhibitory neurotransmitter GABA ([@bib0078]).

2.7. Summary and future directions {#sec0013}
----------------------------------

Stroke is one of the most important causes of acquired epilepsy, particularly in the adult population. Identifying cellular and molecular factors relevant to the development of post-stroke epilepsy therefore represents an area of great clinical need. An elevation in extracellular cerebral glutamate levels has been demonstrated post-stroke, particularly in the hyper-acute phase, in both animal and human studies. While early studies showed higher glutamate levels were associated with worsening of infarct growth, more recent Magnetic Resonance Spectroscopy data suggests that glutamate may form part of a metabolic signature of hyper-perfused tissue which is associated with relatively better clinical outcomes after reperfusion therapy.

There is also significant evidence to support the role of glutamate in the initiation and propagation of seizure activity as well as the process of epileptogenesis. In this setting excessive glutamate activity may be mediated by a combination of aberrant signalling via glutamate receptors, down-regulation of glutamate transporters leading to decreased uptake of glutamate from the extracellular space, or enzymatic dysfunction. Furthermore, treatments that antagonise glutamate receptors or up-regulate glutamate transporters may attenuate this risk, although whether this applies to post-stroke epileptogenesis is unclear. There are thus far no studies that have correlated excessive glutamate levels in acute stroke with the development of epilepsy; only one small study has demonstrated an association between plasma glutamate levels in those with early post-stroke seizures compared with those without early seizures ([@bib0053]).

The advent of 7T MRI technology represents a new opportunity to study intracerebral glutamate levels following stroke in an in-vivo setting, both through Magnetic Resonance Spectroscopy and utilising the *GluCEST* technique. Accordingly we will be able to better understand the temporal changes in glutamate levels after a stroke and identify the optimal time point for glutamate receptor antagonism as an anti-epileptogenic strategy. One caveat is that *GluCEST* contrast is pH dependent and needs to be interpreted in the setting of tissue acidosis, and non-invasive imaging techniques cannot necessarily differentiate between extracellular and intracellular glutamate content. The non-selective, competitive AMPA receptor antagonist perampanel represents a possible anti-epileptogenic agent; it has shown neuroprotective effects in animal models and has an established role in the treatment of epilepsy.

While the search for anti-epileptogenic therapies has thus far been a challenging one, developing a better understanding of the pathogenesis of post-stroke epileptogenesis and implementing potential neuro-protective strategies represents an opportunity to improve the quality of lives of those suffering from a common and serious long term sequela of stroke.
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